Memantine may reduce fractures and cholinesterase inhibitors may increase syncope in dementia: new systematic review

shutterstock_79586893

Last week I blogged about a study that showed how some dementia drugs may help reduce the progression of the disease and delay admission to care homes for people with the condition.

This new systematic review carried out by a research team from Harvard Medical School investigates the potential side effects of two dementia drugs:

  1. Memantine
  2. Cholinesterase inhibitors

The outcomes investigated are:

  • Falls
  • Syncope (Temporary loss of consciousness caused by a fall in blood pressure)
  • Fracture
  • Accidental injury

Researchers carried out a systematic search on a range of databases to find randomised controlled trials and extension studies of cholinesterase inhibitors and memantine that reported falls, syncope, and related events in cognitively impaired older adults living in the community and in nursing homes. They found 54 studies to include in their analysis.

The results showed that, when compared with placebo:

  • Memantine use was associated with fewer fractures (OR=0.21, 95% CI=0.05-0.85)
  • Memantine use was associated with no effect on falls (OR=0.92, 95% CI=0.72-1.18), syncope (OR=1.04, 95% CI=0.35-3.04) and accidental injury (OR=0.80, 95% CI=0.56-1.12).
  • Use of cholinesterase inhibitors was associated with greater risk of syncope (odds ratio (OR)=1.53, 95% confidence interval (CI)=1.02-2.30)
  • Use of cholinesterase inhibitors was associated with no effect on falls (OR=0.88, 95% CI=0.74-1.04), fracture (OR=1.39, 95% CI=0.75-2.56) and accidental injury (OR=1.13, 95% CI=0.87-1.45)
  • There was no differential effect according to type and severity of cognitive impairment, residential status, or length of follow-up, although because of underreporting and small number of events, a potential benefit or risk cannot be excluded.

The authors concluded that:

Memantine may have a favorable effect on fracture, with no effects on other events. More research is needed to confirm the reduction in fractures observed for memantine.

Cholinesterase inhibitors may increase the risk of syncope, with no effects on falls, fracture, or accidental injury in cognitively impaired older adults.

Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011 Jun;59(6):1019-31. doi: 10.1111/j.1532-5415.2011.03450.x. Epub 2011 Jun 7. [PubMed abstract]

Share on Facebook Tweet this on Twitter Share on LinkedIn Share on Google+
Mark as read
Create a personal elf note about this blog
Profile photo of Andre Tomlin

Andre Tomlin

André Tomlin is an Information Scientist with 20 years experience working in evidence-based healthcare. He's worked in the NHS, for Oxford University and since 2002 as Managing Director of Minervation Ltd, a consultancy company who do clever digital stuff for charities, universities and the public sector. Most recently André has been the driving force behind the Mental Elf and the National Elf Service; an innovative digital platform that helps professionals keep up to date with simple, clear and engaging summaries of evidence-based research. André is a Trustee at the Centre for Mental Health and an Honorary Research Fellow at University College London Division of Psychiatry. He lives in Bristol, surrounded by dogs, elflings and lots of woodland!

More posts - Website

Follow me here –